Get started
Work

699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.095
Authors: J.E. Rosenberg, M.D. Galsky, A.V. Balar, Y. Loriot, A. Necchi, J. Hoffman-Censits, S. Srinivas, A. Drakaki, A. Javery, B. Nelson, H.X. Huang, X. Shen, M.S. van der Heijden
Institutions: Memorial Sloan Kettering Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Université Paris-Sud, Université Paris-Saclay, Institut Gustave Roussy, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Stanford Medicine, University of California, Los Angeles, Syneos Health (United States), Genentech, The Netherlands Cancer Institute
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Sanofi, Gilead Sciences, F. Hoffmann-La Roche, Meso Scale Diagnostics, Exelixis, Clovis Oncology, Incyte, Seagen, Astellas Pharma, Ipsen, Bavarian Nordic, Genentech, Kite Pharma, Foundation Medicine, Cilag
OpenAlex ID: W3202746846
FWCI: 1.478
Cites:
Cited by: 7
Related to: 10